Principal Financial Group Inc. Boosts Stock Position in Cellebrite DI Ltd. $CLBT

Principal Financial Group Inc. raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,156,166 shares of the company’s stock after purchasing an additional 545,334 shares during the quarter. Principal Financial Group Inc.’s holdings in Cellebrite DI were worth $29,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after buying an additional 850 shares during the last quarter. CWM LLC grew its stake in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the period. SkyView Investment Advisors LLC increased its holdings in Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares during the last quarter. Alamea Verwaltungs GmbH increased its holdings in Cellebrite DI by 4.3% in the 4th quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after acquiring an additional 1,018 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in Cellebrite DI by 45.1% in the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after acquiring an additional 1,238 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 158,191 shares of company stock valued at $2,479,438 in the last three months. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $15.44 on Monday. The company has a 50 day moving average of $14.01 and a 200 day moving average of $14.40. The stock has a market cap of $3.85 billion, a P/E ratio of 55.14, a P/E/G ratio of 1.91 and a beta of 1.17. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98.

Analysts Set New Price Targets

CLBT has been the topic of several recent research reports. Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. DA Davidson started coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.